Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

enGene Therapeutics Inc. - Common Stock (NQ:ENGN)

1.925 +0.025 (+1.32%)
Streaming Delayed Price Updated: 10:48 AM EDT, Jul 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about enGene Therapeutics Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
Via The Motley Fool
News headline image
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Are EnGene Holdings Shares Trading Lower Friday? ↗
EnGene Holdings Inc. shares are trading lower Friday after the company, reported its financial results for the second quarter. 
Via Benzinga
Unusual volume stocks are being observed in Monday's session. ↗
Via Chartmill
News headline image
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain ↗
enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk... 
Via MarketBeat
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
News headline image
This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial ↗
enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing. 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
ENGN Stock Soars On Hopeful Data From Bladder Cancer Study ↗
The company is now looking forward to submitting an application for approval of the cancer therapy to the U.S. Food and Drug Administration in the second half of 2026. 
Via Stocktwits
News headline image
Get insights into the top gainers and losers of Tuesday's pre-market session. ↗
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
enGene Holdings Inc (NASDAQ:ENGN) Posts Wider-Than-Expected Q3 Loss as R&D Spending Doubles ↗
enGene posts wider-than-expected Q3 loss as R&D spending doubles. The biotech advances its pivotal LEGEND trial and secures key FDA RMAT designation. 
Via Chartmill
News headline image
enGene Posts 78% Expense Jump in Q3 ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Why enGene Holdings Stock Is Trading Higher ↗
enGene shares are trading higher by 6.7% during Friday's session. The company announced it generated approximately $60 million in proceeds from a private placement. 
Via Benzinga
News headline image
IBM Posts Weak Sales, Joins Garrett Motion, Beyond And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ENGN Stock Earnings: enGene Holdings Misses EPS for Q2 2024 ↗
ENGN stock results show that enGene Holdings missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.